Samuel Waksal

Samuel Waksal is an American businessman and biopharmaceutical executive, best known as the founder of ImClone Systems, a biotechnology company focused on cancer treatments. He gained notoriety in the early 2000s due to a scandal involving insider trading, where he sold his company shares based on non-public information about regulatory setbacks for a key drug, Erbitux. His actions led to legal consequences, including a prison sentence. The case is often referenced in discussions about corporate ethics and the importance of transparency in financial markets. Waksal's story highlights the potential consequences of unethical behavior in the business world.